<DOC>
	<DOCNO>NCT00868764</DOCNO>
	<brief_summary>This study aim evaluate effect age BMI pharmacokinetics safety Sancuso® .</brief_summary>
	<brief_title>An Investigation Effect Age BMI Pharmacokinetics Transdermal Granisetron</brief_title>
	<detailed_description>Sancuso® ( granisetron transdermal system [ TDS ] patch ) approve United States ( US ) Food Drug Administration ( FDA ) September 2008 , indicate prevention nausea vomit patient receive moderately and/or highly emetogenic chemotherapy regimens 5 consecutive day ' duration . While vivo pharmacokinetic study Sancuso® healthy adult subject receive chemotherapy conduct , limited data subject alter skin integrity due advance age poor nutritional status relate chronic illness . In addition , available data suggest granisetron deliver subcutaneous fat release compartment time . It possible individual vary nutritional status resultant difference subcutaneous fat would differences pharmacokinetics .</detailed_description>
	<mesh_term>Granisetron</mesh_term>
	<criteria>Healthy male female subject : Part I Aged ≥ 65 year screen Control group : age ≥ 18 45 year screen Part II Aged 18 60 year , inclusive , screen Part I BMI 20.0 29.9 kg/m² , inclusive Part II Underweight ( BMI &lt; 18.5 kg/m² ) obese ( BMI 30.0 39.9 kg/m² , inclusive ) Control group : BMI 20.0 24.9 kg/m² , inclusive Current previous disease , disorder , allergy condition could affect study conduct laboratory assessment , present undue risk study medication procedure . Physical examination screen investigation result indicate subject unfit study . Scarring upper arm . Positive virology , urine drug abuse pregnancy test result ( female subject childbearing potential ) . Recent use prescribe overthecounter medication . Received investigational drug within 3 month ( 90 day ) prior patch application . Loss ≥ 400 mL blood ( e.g . blood donor ) within previous 3 month . Average weekly alcohol consumption &gt; 21 unit ( male ) 14 unit ( female ) , habitually smoke ≥ 5 cigarette equivalent tobacco per day within 6 month patch application . Lactating female subject female subject childbearing potential willing use acceptable form contraception 90 day study . Employee investigator study centre , direct involvement propose study study direction investigator study centre , well family member employee investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Effect age</keyword>
	<keyword>Effect body fat</keyword>
	<keyword>Granisetron</keyword>
	<keyword>Pharmacokinetic profile</keyword>
	<keyword>Sancuso® patch</keyword>
	<keyword>Transdermal</keyword>
</DOC>